Nanjing Vishee Medical Technology Co., Ltd (SHA:688580)
38.70
-0.10 (-0.26%)
Oct 19, 2026, 3:00 PM CST
SHA:688580 Revenue
Nanjing Vishee Medical Technology had revenue of 120.40M CNY in the quarter ending June 30, 2026, with 5.11% growth. This brings the company's total for the last twelve months to 478.71M, up 14.27% year-over-year. In the year 2025, Nanjing Vishee Medical Technology had annual revenue of 462.73M with 15.66% growth. That makes Nanjing Vishee Medical Technology the 25,230th largest company in the world by revenue and 4,489th in China.
Revenue (ttm)
478.71M
Revenue Growth
+14.27%
P/S Ratio
7.74
Revenue / Employee
752.69K
Employees
636
Market Cap
3.70B
Revenue by Segment
Fiscal year ended Dec 31, 2025 See the full SHA:688580 breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 462.73M | 62.67M | 15.66% |
| Dec 31, 2024 | 400.06M | -62.16M | -13.45% |
| Dec 31, 2023 | 462.22M | 140.60M | 43.72% |
| Dec 31, 2022 | 321.62M | -108.42M | -25.21% |
| Dec 31, 2021 | 430.04M | 51.68M | 13.66% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Guangdong Biolight Meditech | 1.10B |
| Zhejiang Orient Gene Biotech | 1.01B |
| SWS Hemodialysis Care | 913.38M |
| Shanghai Aohua Photoelectricity Endoscope | 793.05M |
| Hangzhou AGS MedTech | 592.88M |
| Ningbo David Medical Device | 584.68M |
| Contec Medical Systems Co.,Ltd | 476.33M |
| Medprin Regenerative Medical Technologies | 400.85M |